STOCK TITAN

Terns Pharmaceuticals, Inc. - TERN STOCK NEWS

Welcome to our dedicated page for Terns Pharmaceuticals news (Ticker: TERN), a resource for investors and traders seeking the latest updates and insights on Terns Pharmaceuticals stock.

Terns Pharmaceuticals, Inc. (Nasdaq: TERN) is a clinical-stage biopharmaceutical company with a mission to innovate and develop small-molecule, molecularly-targeted, oral therapies for the treatment of serious diseases, including liver diseases and cancers. Based in San Mateo, California and Shanghai, Terns leverages its expertise in disease biology and medicinal chemistry to advance its growing pipeline of drugs aimed at addressing significant unmet medical needs globally.

The company is renowned for its cost-efficient drug discovery model and robust clinical development capabilities, especially within China. Terns Pharmaceuticals is focused on developing a portfolio of small-molecule candidates tailored for non-alcoholic steatohepatitis (NASH), oncology, and obesity.

One of the company's flagship programs is the TERN-501, an investigational orally administered thyroid hormone receptor-β (THR-β) agonist aimed at treating NASH. The Phase 2a DUET clinical trial revealed promising results, showing significant impacts on liver fat content and fibro-inflammation markers within a short period. This positions TERN-501 as a potential leading therapy for NASH.

Additionally, Terns is developing TERN-701, an allosteric BCR-ABL inhibitor for chronic myeloid leukemia (CML), and TERN-601, a small-molecule GLP-1 receptor agonist for obesity. Both candidates have shown encouraging preclinical and early clinical data, promising significant advancements in their respective fields.

Financially, as of the latest quarter, Terns Pharmaceuticals reported cash, cash equivalents, and marketable securities amounting to $266.6 million, supporting the planned operating expenses into 2026. Recent clinical trials and corporate updates highlight the company's ongoing dedication to addressing global health challenges through innovative drug development.

For more information, please visit their website at www.ternspharma.com.

Rhea-AI Summary
Terns Pharmaceuticals, Inc. (TERN) to participate in fireside chat at JMP Securities Hematology and Oncology Summit. The clinical-stage biopharmaceutical company is developing small-molecule product candidates for serious diseases such as oncology, obesity, and NASH.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
6.97%
Tags
conferences
-
Rhea-AI Summary
Terns Pharmaceuticals, a clinical-stage biopharmaceutical company (Nasdaq: TERN), announced the passing of Senthil Sundaram, their recently retired CEO, on November 22, 2023. Sundaram had a distinguished career in the life sciences industry, serving as CFO of Nightstar Therapeutics plc and in various positions at Intercept Pharmaceuticals, Inc. Prior to joining Terns, he was involved in multiple private and public equity offerings and business development efforts. Memorial contributions may be made in his name to the Peritoneal Cancer Foundation (PCF) at Home. Sundaram's legacy lives on through the PCF, a charity he formed to support research and raise awareness of peritoneal cancer.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
5.96%
Tags
none
-
Rhea-AI Summary
Terns Pharmaceuticals, Inc. (TERN) reports progress in clinical development programs for CML, obesity, and NASH. Anticipates positive proof of concept readouts in 2024. Financial results show $267 million cash expected to support operations into 2026.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
5.34%
Tags
Rhea-AI Summary
TERN-501: Terns Pharmaceuticals Announces Positive Late-Breaking Data from Phase 2a DUET Clinical Trial for NASH Treatment
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4.26%
Tags
-
Rhea-AI Summary
TERN: Terns Pharmaceuticals Announces Participation in Investor Conferences in November
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-21.89%
Tags
conferences
-
Rhea-AI Summary
Terns Pharmaceuticals, Inc. has granted equity inducement awards to three new non-executive employees under the Inducement Plan. The options to purchase 109,000 shares of Terns common stock were granted with a 10-year term and an exercise price of $5.25 per share. The options vest over four years.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.44%
Tags
none
Rhea-AI Summary
Terns Pharmaceuticals has initiated a Phase 1 clinical trial for TERN-601, their oral small-molecule GLP-1R agonist candidate for obesity. The trial aims to assess the safety, tolerability, pharmacokinetics, and pharmacodynamics of TERN-601 in healthy adults with obesity or overweight. The company anticipates reporting 28-day proof of concept data in the second half of 2024.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.62%
Tags
-
Rhea-AI Summary
Terns Pharmaceuticals to participate in upcoming investor conferences
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.98%
Tags
conferences
-
Rhea-AI Summary
Terns Pharmaceuticals grants equity inducement awards to two new non-executive employees.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.2%
Tags
none
Rhea-AI Summary
Terns Pharmaceuticals grants equity inducement awards to new employees
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.95%
Tags
none

FAQ

What is the current stock price of Terns Pharmaceuticals (TERN)?

The current stock price of Terns Pharmaceuticals (TERN) is $5.79 as of November 22, 2024.

What is the market cap of Terns Pharmaceuticals (TERN)?

The market cap of Terns Pharmaceuticals (TERN) is approximately 488.4M.

What does Terns Pharmaceuticals, Inc. specialize in?

Terns Pharmaceuticals specializes in discovering and developing molecularly-targeted, oral, small-molecule drugs for liver diseases and cancers.

Where is Terns Pharmaceuticals located?

Terns Pharmaceuticals is based in San Mateo, California and Shanghai, China.

What is TERN-501 and what disease does it target?

TERN-501 is an investigational orally administered thyroid hormone receptor-β (THR-β) agonist developed for the treatment of non-alcoholic steatohepatitis (NASH).

What are the main therapeutic areas Terns Pharmaceuticals focuses on?

Terns Pharmaceuticals focuses on oncology, obesity, and non-alcoholic steatohepatitis (NASH).

What is the significance of TERN-701?

TERN-701 is an allosteric BCR-ABL inhibitor for chronic myeloid leukemia (CML) and represents a novel class of therapy with superior efficacy and safety profiles.

How is Terns Pharmaceuticals funded for its operations?

Terns Pharmaceuticals reported cash, cash equivalents, and marketable securities amounting to $266.6 million, which they expect to support planned operating expenses into 2026.

What recent achievement has Terns Pharmaceuticals made in clinical trials?

Terns Pharmaceuticals recently announced positive top-line data from its Phase 2a DUET clinical trial of TERN-501 for NASH, showing significant improvements in liver fat content and fibro-inflammation markers.

What is TERN-601 being developed for?

TERN-601 is a small-molecule GLP-1 receptor agonist being developed for the treatment of obesity.

What is the main objective of Terns Pharmaceuticals?

The main objective of Terns Pharmaceuticals is to bring novel, effective small-molecule therapies to market that address significant unmet medical needs globally.

Where can I find more information about Terns Pharmaceuticals' research and development activities?

You can find more information about Terns Pharmaceuticals' research and development activities on their official website at www.ternspharma.com.

Terns Pharmaceuticals, Inc.

Nasdaq:TERN

TERN Rankings

TERN Stock Data

488.40M
77.26M
0.14%
97.69%
5.38%
Biotechnology
Pharmaceutical Preparations
Link
United States of America
FOSTER CITY